Current Cardiology Reports

, 13:387

Update on the Management of Atrial Fibrillation: Anticoagulation and Medical Therapy

Authors

  • Shueh Hao Lim
    • Division of CardiologyThe Johns Hopkins University School of Medicine
  • Hugh Calkins
    • Division of CardiologyThe Johns Hopkins University School of Medicine
    • Division of CardiologyThe Johns Hopkins University School of Medicine
    • The Johns Hopkins Hospital
Article

DOI: 10.1007/s11886-011-0199-9

Cite this article as:
Lim, S.H., Calkins, H. & Sinha, S.K. Curr Cardiol Rep (2011) 13: 387. doi:10.1007/s11886-011-0199-9
  • 193 Views

Abstract

2010 saw the introduction of dabigatran (Pradaxa; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT), following US Food and Drug Administration approval, into daily clinical practice in the United States as an alternative to Coumadin (Bristol-Myers-Squibb, New York, NY) therapy. Dronedarone (Multaq; Sanofi-Aventis, Bridgewater, NJ), originally approved for use in the United States in 2009, has seen further widespread deployment in contemporary clinical practice. Intravenous vernakalant (Cardiome Pharm, Vancouver, B.C., Canada; Merck & Co., Whitehouse Station, NJ) is being considered for approval in the United States and may serve as an alternative to current agents for safe and efficacious acute conversion from atrial fibrillation. We focus primarily on new information concerning these and other antiarrhythmic drug and anticoagulation therapies. We provide brief updates of recently published articles along with our perspective on how they will likely alter clinical practice now and in the future.

Keywords

Atrial fibrillationDabigatranDronedaroneVernakalantAnticoagulationMedical therapy

Clinical Trial Acronyms

ACT

Atrial Arrhythmia Conversion Trial

AF-CHF

Atrial Fibrillation and Congestive Heart Failure

AFFIRM

Atrial Fibrillation Follow-up Investigation of Rhythm Management

ANDROMEDA

Antiarrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease

ARISTOTLE

Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation

ATHENA

A Trial with Dronedarone to Prevent Hospitalization or Death in Patients with Atrial Fibrillation

AVERROES

Apixaban Versus Acetylsalicylic Acid to Prevent Strokes

AVRO

A Phase III Superiority Study of Vernakalant Versus Amiodarone in Subjects with Recent Onset Atrial Fibrillation

DIONYSOS

Efficacy and Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients with Persistent Atrial Fibrillation

ENGAGE AF-TIMI 48

Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation

RACE

Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation

RACE II

Rate Control Efficacy in Permanent Atrial Fibrillation

RE-LY

Randomized Evaluation of Long-Term Anticoagulation Therapy

ROCKET AF

Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation

VALIANT

Valsartan in Acute Myocardial Infarction Trial

Copyright information

© Springer Science+Business Media, LLC 2011